Theriva Biologics (TOVX) catalysts

Upcoming FDA decisions and readouts we track for Theriva Biologics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Theriva Biologics (TOVX, listed on Nasdaq). It concerns VCN-01 (Metastatic pancreatic ductal adenocarcinoma (oncolytic adenovirus)).

First on the list: the Phase 2A readout for VCN-01 (Metastatic pancreatic ductal adenocarcinoma (oncolytic adenovirus)), guided by the company to Q3 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: TOVX
Next catalyst: Q3 2027
Type: Phase 2A readout
Listed options: No

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Theriva Biologics TOVX · Nasdaq	VCN-01	Metastatic pancreatic ductal adenocarcinoma (oncolytic adenovirus)	Q3 2027 company guidance	Phase 2A readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing states "initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027," with enrolment completing in H2 2026. Source: 8-K exhibit 99.1, filed 06 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Arcus Biosciences (RCUS)First-line clear cell renal cell carcinoma; Second-line clear cell renal cell carcinoma; First-line metastatic pancreatic ductal adenocarcinoma
Fractyl Health (GUTS)Type 2 diabetes (pancreatic gene therapy); Post-GLP-1 weight maintenance — 6-month randomised data; Post-GLP-1 weight maintenance — one-year data
Jazz Pharmaceuticals (JAZZ)HER2-positive first-line gastroesophageal adenocarcinoma